Anhui Huaren Health Pharmaceutical (301408)

Search documents
华人健康: 第五届董事会第十次会议决议公告
Zheng Quan Zhi Xing· 2025-07-03 16:05
本公司及董事会全体成员保证信息披露内容真实、准确和完整,没有虚假记 载、误导性陈述或者重大遗漏。 一、董事会会议召开情况 证券代码:301408 证券简称:华人健康 公告编号:2025-047 安徽华人健康医药股份有限公司 安徽华人健康医药股份有限公司(以下简称"公司")第五届董事会第十次 会议已于 2025 年 6 月 26 日以书面、邮件送达形式发出通知,并于 2025 年 6 月 名,实到董事 9 名,其中董事鲁勖、殷俊、刘亮、程谋以通讯表决方式出席。本 次会议由公司董事长何家乐先生召集和主持,公司监事和高级管理人员列席了会 议。本次会议的召集和召开符合相关法律法规及《公司章程》的规定,做出的决 议合法有效。 二、董事会会议审议情况 本次会议审议并通过如下议案: 根据《中华人民共和国公司法》《关于新 <公司法> 配套制度规则实施相关过 渡期安排》《上市公司章程指引》等相关法律法规的规定,公司将不再设置监事 会,《公司法》规定的监事会的职权由董事会审计委员会行使,《安徽华人健康 医药股份有限公司监事会议事规则》相应废止,《安徽华人健康医药股份有限公 司章程》中相关条款亦作出相应修订,同时提请公司股东大会授 ...
华人健康: 董事、高级管理人员离职管理制度
Zheng Quan Zhi Xing· 2025-07-03 16:05
根据《公司章程》规定,高级管理人员是指公司总裁、副总裁、董事会 秘书、财务总监等董事会认定的高级管理人员。 第二章 离职情形与生效条件 董事提出辞任的,公司应当在60日内完成补选,确保董事会构成符合法 律、行政法规、部门规章及公司章程的规定。 公司董事、高级管理人员应当在辞职报告中说明辞职时间、辞职原因、 辞去的职务、辞职后是否继续在公司及其控股子公司任职(如继续任职, 说明继续任职的情况)等情况。 安徽华人健康医药股份有限公司 第一章 总则 董事、高级管理人员在任职期间出现《公司法》《公司章程》规定的不 得担任董事、高级管理人员情形的,或者被中国证监会采取不得担任上 市公司董事、高级管理人员的市场禁入措施,期限尚未届满的,相关董 事、高级管理人员应当立即停止履职并由公司按相应规定解除其职务。 董事、高级管理人员在任职期间出现被证券交易场所公开认定为不适合 担任上市公司董事、高级管理人员等法律法规、深圳证券交易所规定的 其他情形的,公司应当在该事实发生之日起30日内解除其职务,深圳证 券交易所另有规定的除外。 独立董事、董事会秘书的离职、解聘应当按照本公司《独立董事工作制 度》《董事会秘书工作细则》具体要求执 ...
华人健康: 控股子公司管理制度
Zheng Quan Zhi Xing· 2025-07-03 16:05
安徽华人健康医药股份有限公司 第一章 总则 第一条 为加强安徽华人健康医药股份有限公司(以下简称"公司"或"本公司") 及控股子公司的管理控制,规范公司内部运作机制,维护公司和投资者 的合法权益。根据《中华人民共和国公司法》、《中华人民共和国证券 法》、《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市 公司规范运作》等法律、法规、规范性文件以及《安徽华人健康医药股 份有限公司章程》(以下简称"《公司章程》")的规定,结合本公司 实际情况,制定本制度。 第二条 本制度所称"控股子公司"是指公司根据发展战略规划和突出主业、提 高公司核心竞争力需要而依法设立的,具有独立法人资格主体的公司。 其设立形式包括: (一)公司独资设立的全资子公司; (二)公司与其他公司或自然人共同出资设立的,公司控股 50%以上(不 含 50%),或未达到 50%但能够决定其董事会半数以上成员的组成, 或者通过协议或其他安排能够实际控制的公司; (三)公司通过并购形成的控股子公司。 第三条 本制度适用于公司的各类控股子公司。 第四条 公司主要通过行使表决权以及向控股子公司委派董事、监事(如有)、 高级管理人员和日常监管两条途径 ...
华人健康: 关于召开2025年第二次临时股东大会的通知
Zheng Quan Zhi Xing· 2025-07-03 16:05
Meeting Overview - The company will hold its second extraordinary general meeting of shareholders on July 18, 2025, at 14:30, combining on-site and online voting methods [1][2] - The online voting will be available through the Shenzhen Stock Exchange trading system and internet voting system from 9:15 to 15:00 on the same day [1][2] Voting Rights and Procedures - All shareholders registered by July 10, 2025, are entitled to attend the meeting and vote, either in person or by proxy [2][3] - Shareholders can only choose one voting method: on-site or online, with the first valid vote being counted in case of duplicate votes [2][3] Agenda Items - Proposals submitted for voting have been approved by the board and require at least two-thirds of the voting rights held by attending shareholders to pass [3] - The company will separately count and disclose the voting results of minority investors [3] Registration Details - Registration for the meeting can be done on-site, via mail, or email, with specific times and locations provided [4] - Natural persons must present identification and proof of shareholding, while legal entities must provide additional documentation [4] Online Voting Process - The company will provide a platform for online voting, with detailed procedures outlined for shareholders to follow [5][6] - Shareholders must complete identity verification to participate in online voting [5][6] Contact Information - The meeting will take place in Hefei, Anhui Province, with contact details provided for inquiries [5]
华人健康: 内部审计制度(2025年7月)
Zheng Quan Zhi Xing· 2025-07-03 16:05
Core Viewpoint - The internal audit system of Anhui Huaren Health Pharmaceutical Co., Ltd. aims to ensure compliance, asset security, and the authenticity of financial reporting while enhancing operational efficiency and supporting the company's strategic development [2][4]. Group 1: Internal Control Objectives - Internal control is a process implemented by the board of directors, audit committee, management, and all employees to achieve control objectives [2]. - The goals of internal control include ensuring legal compliance in management, asset security, and the authenticity and completeness of financial reports [2]. Group 2: Internal Audit Structure - The company has established an internal audit department responsible for supervising business activities, risk management, internal controls, and financial information [4][6]. - The internal audit department reports to the board of directors and is supervised by the audit committee [4][6]. Group 3: Responsibilities of Internal Audit - The internal audit department is tasked with evaluating the effectiveness of internal controls, the authenticity of financial information, and the efficiency of business activities [4][5]. - Internal audit personnel must possess professional qualifications and adhere to ethical standards while conducting audits [4][10]. Group 4: Reporting and Evaluation - The internal audit department must report any significant deficiencies or risks in internal controls to the audit committee promptly [5][6]. - The audit committee is responsible for reviewing internal audit reports and providing written assessments of the effectiveness of internal controls to the board of directors [6][8]. Group 5: Compliance and Accountability - The company must disclose any significant deficiencies in internal controls to the Shenzhen Stock Exchange and outline the measures taken to address these issues [6][9]. - Internal audit personnel are protected by laws and regulations, and any obstruction or retaliation against them is prohibited [4][10].
华人健康: 董事和高级管理人员所持本公司股份及变动管理制度(2025年7月)
Zheng Quan Zhi Xing· 2025-07-03 16:05
Core Points - The document outlines the management system for the shares held by directors and senior management of Anhui Huaren Health Pharmaceutical Co., Ltd, emphasizing the need for compliance with relevant laws and regulations [2][3][12] - It specifies the procedures for reporting share transactions by directors and senior management, including timelines for notification and disclosure [4][5][20] - The document establishes restrictions on the transfer of shares by directors and senior management, including limits on the number of shares that can be sold within a year and conditions under which shares cannot be transferred [6][8][19] Group 1 - The management system is established to enhance the oversight of shares held by directors and senior management, in accordance with the Company Law and Securities Law [2][3] - Directors and senior management must notify the board secretary in writing before buying or selling shares, and the board secretary is responsible for managing and verifying the information [4][12] - The document outlines the calculation of transferable shares, stating that newly acquired shares can only be transferred under specific conditions [3][5] Group 2 - Restrictions on share transfers include a maximum of 25% of total shares held per year and a six-month lock-up period after leaving the company [4][6][19] - Certain conditions prohibit directors and senior management from trading shares, such as during the period before financial report announcements and when under investigation for violations [8][18] - The document mandates that any changes in shareholding must be reported to the Shenzhen Stock Exchange within two trading days, including details of the transaction [20][9]
华人健康: 关于修订《公司章程》的公告
Zheng Quan Zhi Xing· 2025-07-03 16:05
证券代码:301408 证券简称:华人健康 公告编号:2025-048 安徽华人健康医药股份有限公司 本公司及董事会全体成员保证公告内容真实、准确和完整,没有虚假记载、 误导性陈述或重大遗漏。 二、修订《公司章程》的情况 综上,根据《中华人民共和国公司法》《中华人民共和国证券法》《上市公 司章程指引》《上市公司治理准则》《上市公司独立董事管理办法》《深圳证券 交易所创业板股票上市规则》《深圳证券交易所上市公司自律监管指引第 2 号— —创业板上市公司规范运作》等相关法律法规及规范性文件的规定,公司拟对《公 司章程》中相关条款进行变更,将监事会的职责平移至董事会审计委员会。《公 司章程》的具体条款修订对比情况详见后附的《公司章程》修订对照表。《公司 章程》中涉及"股东大会"的表述更新为"股东会","或"的表述更新为"或 者",对部分中文数字更新为阿拉伯数字(含百分比数字),在不涉及其他内容 修订的情况下,上述调整以及相关条款项目的序号调整不再逐一列示。 修订后的《公司章程》全文详见公司同日在巨潮资讯网(www.cninfo.com.cn) 披露的《公司章程》(2025 年 7 月修订)。 三、其他事项 董事会提 ...
华人健康: 累积投票制实施细则(2025年7月)
Zheng Quan Zhi Xing· 2025-07-03 16:05
第一条 为进一步完善安徽华人健康医药股份有限公司(以下简称"公司") 法人治理结构,维护中小股东的利益、规范公司选举董事行为,根据 《中华人民共和国公司法》(以下简称"《公司法》")、《中华人 民共和国证券法》(以下简称"《证券法》")、《上市公司治理准 则》等法律、法规、规章、规范性文件及《安徽华人健康医药股份有 限公司章程》(以下简称"公司章程")的规定,结合公司实际情况, 特制定本实施细则。 第二条 本实施细则所称"累积投票制",是指股东会就选举两名以上董事时 采用的一种投票方式。即公司股东会选举董事时,股东所持有表决权 的每一股份拥有与该次股东会拟选举董事总人数相等的投票权,股东 拥有的投票权等于该股东持有股份数与应选董事人数的乘积。股东既 可以用所有投票权集中投票选举一名候选董事,也可以分散投票给数 名候选董事。 第三条 股东会选举产生的董事人数及结构应符合公司章程的规定。 第四条 本实施细则所称"董事"包括非独立董事和独立董事。职工代表董事 由公司职工代表大会选举产生或更换,不适用于本实施细则的相关规 定。 第五条 在股东会上,拟选举两名及两名以上的董事时,董事会应当在召开股 东会通知中,表明该次 ...
华人健康: 信息披露暂缓与豁免管理制度
Zheng Quan Zhi Xing· 2025-07-03 16:05
安徽华人健康医药股份有限公司 第一章 总则 第二章 信息披露暂缓与豁免的适用情形 第一条 为规范安徽华人健康医药股份有限公司(以下简称"公司")信息披 露暂缓与豁免行为,确保公司依法合规履行信息披露义务,保护投资 者的合法权益,根据《中华人民共和国证券法》(以下简称"《证券 法》")、《上市公司信息披露暂缓与豁免管理规定》《深圳证券交 易所创业板股票上市规则》(以下简称"《上市规则》")等相关法 律法规,并结合《公司章程》及公司《信息披露管理制度》等有关规 定,制定本制度。 第二条 公司和其他信息披露义务人暂缓、豁免披露临时报告,在定期报告、 临时报告中豁免披露按照中国证券监督管理委员会(以下简称"中国 证监会")及深圳证券交易所(以下简称"深交所")规定或者要求披 露的内容,适用本制度。 第三条 公司应当审慎确定信息披露暂缓、豁免事项,并采取有效措施防止暂 缓或者豁免披露的信息泄露。 第四条 公司和其他信息披露义务人应当真实、准确、完整、及时、公平地披 露信息,不得滥用暂缓或者豁免披露规避信息披露义务、误导投资者, 不得实施内幕交易、操纵市场等违法行为。 第十四条 公司和其他信息披露义务人应当在年度报告、半 ...
华人健康: 会计师事务所选聘制度
Zheng Quan Zhi Xing· 2025-07-03 16:05
Core Viewpoint - The document outlines the procedures and requirements for selecting and changing accounting firms for Anhui Huaren Health Pharmaceutical Co., Ltd, emphasizing the importance of maintaining independence and quality in the auditing process [1][2][3]. Group 1: General Principles - The audit fees for the accounting firm are determined by the shareholders' meeting [1] - The controlling shareholders and actual controllers are prohibited from designating accounting firms or interfering with the audit committee's independent duties [1] - The selection of accounting firms must comply with relevant laws and regulations, including the Company Law and Securities Law of the People's Republic of China [1][2] Group 2: Requirements for Accounting Firms - Selected accounting firms must possess independent qualifications and meet the requirements set by the China Securities Regulatory Commission [1][2] - Firms must have a fixed workplace, sound organizational structure, and robust internal management systems [1] - The auditing team must include registered accountants who have not faced criminal or administrative penalties related to their professional conduct in the last three years [1][2] Group 3: Selection Procedures - The audit committee, independent directors, or a majority of the board can propose the hiring of an accounting firm [2][3] - The selection process must be competitive, utilizing methods such as competitive negotiation, public bidding, or invitation to tender [2][3] - The company must publicly disclose the selection documents, including evaluation criteria and scoring standards [2][3] Group 4: Evaluation and Reporting - The audit committee is responsible for evaluating the performance of the accounting firm annually and reporting to the board [2][3] - Evaluation criteria must include audit fees, qualifications, quality management, and risk management capabilities [4][5] - Significant changes in audit fees (over 20%) must be disclosed, including reasons for the change [6] Group 5: Change of Accounting Firms - The company must change accounting firms under specific circumstances, such as quality issues or failure to meet obligations [8][9] - The audit committee must communicate with both the outgoing and incoming firms to assess quality and integrity [9][10] - The reasons for changing firms must be disclosed, along with communication details with the previous firm [11][12]